Karyopharm Therapeutics Stock Price, News & Analysis (NASDAQ:KPTI)

$10.18 0.14 (1.39 %)
(As of 01/17/2018 04:00 PM ET)
Previous Close$10.04
Today's Range$10.00 - $10.31
52-Week Range$7.48 - $14.63
Volume111,348 shs
Average Volume192,364 shs
Market Capitalization$480.30 million
P/E Ratio-3.83
Dividend YieldN/A
Beta4.08

About Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics logoKaryopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:KPTI
CUSIPN/A
Phone+1-617-6580600

Debt

Debt-to-Equity RatioN/A
Current Ratio5.75%
Quick Ratio5.75%

Price-To-Earnings

Trailing P/E Ratio-3.82706766917293
Forward P/E Ratio-3.95
P/E GrowthN/A

Sales & Book Value

Annual Sales$150,000.00
Price / Sales3,201.95
Cash FlowN/A
Price / CashN/A
Book Value$3.93 per share
Price / Book2.59

Profitability

Trailing EPS($2.66)
Net Income$-109,570,000.00
Net Margins-67,267.47%
Return on Equity-76.83%
Return on Assets-68.22%

Miscellaneous

Employees108
Outstanding Shares47,180,000

Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc (NASDAQ:KPTI) released its earnings results on Thursday, November, 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.01. Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. View Karyopharm Therapeutics' Earnings History.

When will Karyopharm Therapeutics make its next earnings announcement?

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for Karyopharm Therapeutics.

Where is Karyopharm Therapeutics' stock going? Where will Karyopharm Therapeutics' stock price be in 2018?

7 brokerages have issued twelve-month price targets for Karyopharm Therapeutics' shares. Their predictions range from $14.00 to $23.00. On average, they expect Karyopharm Therapeutics' stock price to reach $17.43 in the next twelve months. View Analyst Ratings for Karyopharm Therapeutics.

What are Wall Street analysts saying about Karyopharm Therapeutics stock?

Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:

  • 1. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (11/7/2017)
  • 2. Cantor Fitzgerald analysts commented, "Support for KPTI’s DLBCL program (SADAL) could build with a presentation at the EHA (Abstract S469) in June." (5/15/2017)
  • 3. HC Wainwright analysts commented, "Although selinexor is still technically on a partial clinical hold in the U.S., due to an omitted table in its most recent investigator's brochure, Karyopharm focused its 4Q call on the steady progress being made in its development across a range of indications. Having received its requested information, we believe the FDA should release the partial clinical hold well in advance of 4/9, and believe this hiccup will have no material impact on enrollment of the selinexor trials. On its call, Karyopharm noted that it had completed enrollment of its Phase 2/3 SEAL trial of selinexor in liposarcoma patients and expects to report topline data in mid-2017. While we do not currently include liposarcoma in our estimates, we note that selinexor had shown promising and durable stable disease outcomes in a Phase 1 study in sarcomas with a better PFS observed than the last prior regimen (19.4 v. 7.7 weeks) with 43% of liposarcoma patients achieving stable disease having a 4+ month response. Separately, Karyopharm provided updates on selinexor in multiple myeloma noting that the expanded STORM trial in penta-refractory myeloma patients was on track to read out in early-2018, the Phase 3 BOSTON trial was expected to start by April, and the Phase 1b/2 STOMP trial was to begin enrollment of a 44- patient Darzalex (daratumumab) combination arm, expected to read out in late-2017/early-2018. As of December, Karyopharm had a cash position of $175.5M, which the company believes sufficient to fund operations through 2018. In 2017, Karyopharm expects its cash burn to be $85-90M. We are maintaining our KPTI price target of $14, based on a sum-of-the-parts DCF consisting of $6 for selinexor in MM, $4 sel in DLBCL, and $4 cash." (3/17/2017)

Who are some of Karyopharm Therapeutics' key competitors?

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the folowing people:

  • Sharon Shacham Ph.D., M.B.A., President, Co-Founder, Chief Scientific Officer, Director (Age 46)
  • Michael G. Kauffman M.D. Ph.D., Co-Founder, Chief Executive Officer and Director (Age 53)
  • Michael Falvey, Chief Financial Officer, Executive Vice President, Treasurer, Principal Financial Officer, Principal Accounting Officer (Age 58)
  • Christopher B. Primiano J.D., M.B.A., Senior Vice President, General Counsel, Secretary (Age 36)
  • Michael J. Todisco CPA, Vice President - Finance, Assistant Treasurer (Age 52)
  • Ran Frenkel RPh., Chief Development Operations Officer (Age 48)
  • Barry E. Greene, Lead Independent Director (Age 53)
  • Mikael Dolsten M.D., Ph.D., Director (Age 58)
  • Mansoor Raza Mirza M.D., Director and Clinical Advisor (Age 56)
  • Garen G. Bohlin, Independent Director (Age 69)

Who owns Karyopharm Therapeutics stock?

Karyopharm Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.32%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

Who bought Karyopharm Therapeutics stock? Who is buying Karyopharm Therapeutics stock?

Karyopharm Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Karyopharm Therapeutics.

How do I buy Karyopharm Therapeutics stock?

Shares of Karyopharm Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Karyopharm Therapeutics' stock price today?

One share of Karyopharm Therapeutics stock can currently be purchased for approximately $10.18.

How big of a company is Karyopharm Therapeutics?

Karyopharm Therapeutics has a market capitalization of $480.30 million and generates $150,000.00 in revenue each year. The company earns $-109,570,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Karyopharm Therapeutics employs 108 workers across the globe.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 Wells Ave, NEWTON CENTER, MA 02459-3298, United States. The company can be reached via phone at +1-617-6580600 or via email at [email protected]


MarketBeat Community Rating for Karyopharm Therapeutics (KPTI)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  410
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Karyopharm Therapeutics (NASDAQ:KPTI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.43$17.43$16.00$15.32
Price Target Upside: 65.83% upside65.83% upside39.98% upside62.27% upside

Karyopharm Therapeutics (NASDAQ:KPTI) Consensus Price Target History

Price Target History for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017Cantor FitzgeraldSet Price TargetBuy$18.00HighView Rating Details
12/12/2017HC WainwrightReiterated RatingBuy$23.00HighView Rating Details
11/3/2017Royal Bank of CanadaReiterated RatingBuy$15.00N/AView Rating Details
11/3/2017Robert W. BairdReiterated RatingBuyN/AView Rating Details
10/13/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
8/8/2017Canaccord GenuitySet Price TargetBuy$18.00HighView Rating Details
4/5/2017WedbushReiterated RatingOutperform$14.00MediumView Rating Details
10/7/2016Leerink SwannReiterated RatingOutperform$18.00N/AView Rating Details
8/30/2016S&P Equity ResearchLower Price Target$9.06 -> $7.55N/AView Rating Details
5/27/2016Raymond James FinancialInitiated CoverageOutperform$13.00N/AView Rating Details
3/15/2016Bank of AmericaDowngradeNeutral -> Underperform$26.00 -> $11.00N/AView Rating Details
3/14/2016JPMorgan Chase & Co.Lower Price TargetOverweight$20.00 -> $19.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$58.00 -> $28.00N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Karyopharm Therapeutics (NASDAQ:KPTI) Earnings History and Estimates Chart

Earnings by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ KPTI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.65)N/AView Earnings Details
11/2/2017Q3 2017($0.64)($0.65)$0.03 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.64)($0.64)$0.23 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.67)($0.71)$0.02 million$0.07 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.65)($0.65)$0.18 million$0.05 millionViewN/AView Earnings Details
11/7/2016Q316($0.81)($0.69)$0.18 million$0.05 millionViewListenView Earnings Details
8/4/2016Q216($0.76)($0.84)$0.18 million$0.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.74)($0.75)$0.30 millionViewN/AView Earnings Details
3/14/2016Q415($0.82)($0.81)$0.30 million$0.03 millionViewListenView Earnings Details
11/9/2015Q315($0.87)($0.85)$0.30 million$0.08 millionViewListenView Earnings Details
8/10/2015Q215($0.77)($0.92)$0.30 million$0.15 millionViewListenView Earnings Details
5/11/2015Q115($0.75)($0.74)$0.30 millionViewListenView Earnings Details
3/16/2015Q414($0.66)($0.79)$0.11 million$0.02 millionViewListenView Earnings Details
11/10/2014Q314($0.53)($0.61)$0.20 million$0.02 millionViewN/AView Earnings Details
8/7/2014Q214($0.51)($0.55)$0.20 million$0.02 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.45)($0.46)$0.25 million$0.17 millionViewN/AView Earnings Details
3/5/2014($0.34)($2.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Karyopharm Therapeutics (NASDAQ:KPTI) Earnings Estimates

2018 EPS Consensus Estimate: ($2.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.64)($0.64)($0.64)
Q2 20181($0.59)($0.59)($0.59)
Q3 20181($0.60)($0.60)($0.60)
Q4 20181($0.61)($0.61)($0.61)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Karyopharm Therapeutics (NASDAQ:KPTI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Karyopharm Therapeutics (NASDAQ KPTI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.71%
Institutional Ownership Percentage: 60.92%
Insider Trades by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)
Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ KPTI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/8/2018Sharon ShachamInsiderSell10,000$10.08$100,800.00723,510View SEC Filing  
12/18/2017Michael KauffmanCEOSell10,000$9.16$91,600.00522,143View SEC Filing  
12/12/2017Christopher Brett PrimianoSVPSell27,042$10.28$277,991.7611,381View SEC Filing  
12/7/2017Sharon ShachamInsiderSell10,000$10.39$103,900.00View SEC Filing  
11/7/2017Christopher Brett PrimianoSVPSell4,958$11.25$55,777.50View SEC Filing  
10/2/2017Christopher Brett PrimianoSVPSell1,500$12.00$18,000.00View SEC Filing  
10/2/2017Mansoor Raza MirzaDirectorSell2,000$12.00$24,000.00View SEC Filing  
9/15/2017Christopher Brett PrimianoSVPSell2,000$11.00$22,000.0012,881View SEC Filing  
9/15/2017Mansoor Raza MirzaDirectorSell2,882$11.00$31,702.002,882View SEC Filing  
9/11/2017Mansoor Raza MirzaDirectorSell118$11.00$1,298.00118View SEC Filing  
8/29/2017Christopher Brett PrimianoSVPSell2,195$10.00$21,950.00View SEC Filing  
6/26/2017Christopher Brett PrimianoSVPSell805$10.03$8,074.15View SEC Filing  
11/14/2016Ran FrenkelInsiderSell3,309$10.06$33,288.5414,691View SEC Filing  
6/23/2016Ltd ChioneMajor ShareholderSell18,824$8.03$151,156.72View SEC Filing  
6/13/2016Ltd ChioneMajor ShareholderSell7,074$8.51$60,199.748,568,744View SEC Filing  
6/9/2016Ltd ChioneMajor ShareholderSell45,541$9.21$419,432.618,605,818View SEC Filing  
6/7/2016Ltd ChioneMajor ShareholderSell40,000$9.24$369,600.008,641,359View SEC Filing  
6/2/2016Ltd ChioneMajor ShareholderSell17,855$9.65$172,300.758,661,359View SEC Filing  
6/1/2016Ltd ChioneMajor ShareholderSell74,664$9.61$717,521.048,713,878View SEC Filing  
5/31/2016Ltd ChioneMajor ShareholderSell17,096$9.66$165,147.368,713,878View SEC Filing  
5/27/2016Ltd ChioneMajor ShareholderSell40,000$9.58$383,200.008,713,878View SEC Filing  
5/26/2016Ltd ChioneMajor ShareholderSell46,122$9.73$448,767.068,772,060View SEC Filing  
5/23/2016Ltd ChioneMajor ShareholderSell93,932$8.54$802,179.288,873,932View SEC Filing  
5/18/2016Ltd ChioneMajor ShareholderSell63,800$8.15$519,970.008,923,932View SEC Filing  
5/16/2016Ltd ChioneMajor ShareholderSell10,400$8.01$83,304.008,967,732View SEC Filing  
5/11/2016Ltd ChioneMajor ShareholderSell31,868$8.24$262,592.328,980,000View SEC Filing  
12/8/2015Mansoor Raza MirzaDirectorSell15,000$15.01$225,150.00View SEC Filing  
4/7/2015Ran FrenkelEVPBuy3,000$31.81$95,430.00View SEC Filing  
4/2/2015Barry E GreeneDirectorBuy3,000$29.31$87,930.00View SEC Filing  
4/2/2015Justin A RenzCFOBuy5,000$29.71$148,550.00View SEC Filing  
1/12/2015Deepika PakianathanDirectorBuy45,454$33.00$1,499,982.00View SEC Filing  
1/12/2015Michael KauffmanCEOSell50,000$33.00$1,650,000.00View SEC Filing  
1/12/2015Sharon ShachamInsiderSell25,000$33.00$825,000.00View SEC Filing  
12/2/2014Mansoor Raza MirzaDirectorSell10,000$43.52$435,200.00View SEC Filing  
12/1/2014Ltd ChioneMajor ShareholderSell278,115$41.92$11,658,580.80View SEC Filing  
11/25/2014Ltd ChioneMajor ShareholderSell242,800$42.40$10,294,720.00View SEC Filing  
11/19/2014Ltd ChioneMajor ShareholderSell65,968$40.09$2,644,657.12View SEC Filing  
11/12/2014Ltd ChioneMajor ShareholderSell164,100$42.83$7,028,403.00View SEC Filing  
11/11/2014Ltd ChioneMajor ShareholderSell54,100$42.51$2,299,791.00View SEC Filing  
11/10/2014Ltd ChioneMajor ShareholderSell65,000$43.40$2,821,000.00View SEC Filing  
11/10/2014Mansoor Raza MirzaDirectorSell5,000$45.05$225,250.00View SEC Filing  
11/6/2014Ltd ChioneMajor ShareholderSell272,784$42.11$11,486,934.24View SEC Filing  
10/29/2014Mansoor Raza MirzaDirectorSell3,500$40.05$140,175.00View SEC Filing  
9/26/2014Marcin CzernikMajor ShareholderSell50,000$42.54$2,127,000.00View SEC Filing  
9/24/2014Marcin CzernikMajor ShareholderSell22,498$40.32$907,119.36View SEC Filing  
9/18/2014Marcin CzernikMajor ShareholderSell12,347$40.24$496,843.28View SEC Filing  
9/17/2014Marcin CzernikMajor ShareholderSell9,569$40.26$385,247.94View SEC Filing  
9/12/2014Ltd ChioneMajor ShareholderSell4,312$41.12$177,309.44View SEC Filing  
9/8/2014Marcin CzernikMajor ShareholderSell35,666$39.92$1,423,786.72View SEC Filing  
9/4/2014Marcin CzernikMajor ShareholderSell12,795$38.07$487,105.65View SEC Filing  
8/27/2014Marcin CzernikMajor ShareholderSell43,699$38.80$1,695,521.20View SEC Filing  
8/25/2014Marcin CzernikMajor ShareholderSell4,389$38.08$167,133.12View SEC Filing  
8/15/2014Marcin CzernikMajor ShareholderSell8,027$39.11$313,935.97View SEC Filing  
8/11/2014Marcin CzernikMajor ShareholderSell36,979$37.30$1,379,316.70View SEC Filing  
7/30/2014Marcin CzernikMajor ShareholderSell21,570$36.20$780,834.00View SEC Filing  
7/29/2014Ltd ChioneMajor ShareholderSell30,000$35.20$1,056,000.00View SEC Filing  
7/23/2014Ltd PlioInsiderSell500,000$35.54$17,770,000.00View SEC Filing  
7/2/2014Michael KauffmanCEOSell200,000$42.50$8,500,000.00View SEC Filing  
6/18/2014Sharon ShachamInsiderSell20,000$41.76$835,200.00View SEC Filing  
6/17/2014Michael KauffmanCEOSell20,000$41.76$835,200.00View SEC Filing  
5/23/2014Deepika PakianathanDirectorBuy114,419$26.18$2,995,489.42View SEC Filing  
5/13/2014Paul BrannellySVPBuy1,000$28.06$28,060.0064,636View SEC Filing  
11/12/2013Deepika PakianathanDirectorBuy312,500$16.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Karyopharm Therapeutics (NASDAQ KPTI) News Headlines

Source:
DateHeadline
Karyopharm Therapeutics Inc (KPTI) Insider Sells $100,800.00 in StockKaryopharm Therapeutics Inc (KPTI) Insider Sells $100,800.00 in Stock
www.americanbankingnews.com - January 9 at 7:16 PM
Karyopharm Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference - NasdaqKaryopharm Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference - Nasdaq
www.nasdaq.com - January 5 at 9:46 AM
Karyopharm Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceKaryopharm Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 8:50 AM
Karyopharm Therapeutics Inc. (KPTI) Receives Average Rating of "Buy" from BrokeragesKaryopharm Therapeutics Inc. (KPTI) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 26 at 11:54 AM
Karyopharm Therapeutics (KPTI) Upgraded to Hold at BidaskClubKaryopharm Therapeutics (KPTI) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - December 23 at 1:28 PM
Karyopharm Therapeutics Inc. (KPTI) CEO Sells $91,600.00 in StockKaryopharm Therapeutics Inc. (KPTI) CEO Sells $91,600.00 in Stock
www.americanbankingnews.com - December 20 at 6:06 PM
Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual MeetingKaryopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting
finance.yahoo.com - December 19 at 5:09 PM
Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual MeetingKaryopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting
finance.yahoo.com - December 19 at 5:09 PM
Karyopharm Therapeutics Target of Unusually High Options Trading (KPTI)Karyopharm Therapeutics Target of Unusually High Options Trading (KPTI)
www.americanbankingnews.com - December 14 at 4:38 AM
Christopher Brett Primiano Sells 27,042 Shares of Karyopharm Therapeutics Inc. (KPTI) StockChristopher Brett Primiano Sells 27,042 Shares of Karyopharm Therapeutics Inc. (KPTI) Stock
www.americanbankingnews.com - December 13 at 6:20 PM
Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting - GlobeNewswire (press release)Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting - GlobeNewswire (press release)
globenewswire.com - December 12 at 10:06 AM
Karyopharm Therapeutics (KPTI) Announces Positive Selinexor Data from the Phase 1b/2 STOMP Study - StreetInsider.comKaryopharm Therapeutics (KPTI) Announces Positive Selinexor Data from the Phase 1b/2 STOMP Study - StreetInsider.com
www.streetinsider.com - December 12 at 10:06 AM
Cantor Fitzgerald Analysts Give Karyopharm Therapeutics (KPTI) a $18.00 Price TargetCantor Fitzgerald Analysts Give Karyopharm Therapeutics (KPTI) a $18.00 Price Target
www.americanbankingnews.com - December 12 at 10:04 AM
Karyopharm Therapeutics (KPTI) Earns "Buy" Rating from HC WainwrightKaryopharm Therapeutics (KPTI) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - December 12 at 8:52 AM
BidaskClub Downgrades Karyopharm Therapeutics (KPTI) to SellBidaskClub Downgrades Karyopharm Therapeutics (KPTI) to Sell
www.americanbankingnews.com - December 9 at 2:24 PM
Insider Selling: Karyopharm Therapeutics Inc. (KPTI) Insider Sells 10,000 Shares of StockInsider Selling: Karyopharm Therapeutics Inc. (KPTI) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - December 8 at 6:20 PM
Karyopharm Therapeutics (KPTI) Rating Lowered to Strong Sell at ValuEngineKaryopharm Therapeutics (KPTI) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - December 6 at 11:26 PM
Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : December 6, 2017Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US : December 6, 2017
finance.yahoo.com - December 6 at 9:51 AM
Karyopharm Therapeutics (KPTI) & The Competition Head-To-Head ContrastKaryopharm Therapeutics (KPTI) & The Competition Head-To-Head Contrast
www.americanbankingnews.com - December 5 at 11:36 PM
Karyopharm Therapeutics Inc. (KPTI) Receives Average Rating of "Buy" from AnalystsKaryopharm Therapeutics Inc. (KPTI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 1 at 5:10 PM
$11.18 Million in Sales Expected for Karyopharm Therapeutics Inc. (KPTI) This Quarter$11.18 Million in Sales Expected for Karyopharm Therapeutics Inc. (KPTI) This Quarter
www.americanbankingnews.com - November 19 at 8:26 PM
Karyopharm Therapeutics Inc. (KPTI) Given "Buy" Rating at HC WainwrightKaryopharm Therapeutics Inc. (KPTI) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - November 19 at 8:16 PM
Karyopharm Therapeutics Inc. (KPTI) Expected to Announce Earnings of -$0.67 Per ShareKaryopharm Therapeutics Inc. (KPTI) Expected to Announce Earnings of -$0.67 Per Share
www.americanbankingnews.com - November 17 at 3:34 AM
Karyopharm Therapeutics Inc. (KPTI) Receives New Coverage from Analysts at H.C. WainwrightKaryopharm Therapeutics Inc. (KPTI) Receives New Coverage from Analysts at H.C. Wainwright
www.americanbankingnews.com - November 15 at 8:28 AM
Karyopharm Therapeutics to Present at the Jefferies 2017 London Healthcare Conference - GlobeNewswire (press release)Karyopharm Therapeutics to Present at the Jefferies 2017 London Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 13 at 11:44 AM
Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage SoarsYour Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars
seekingalpha.com - November 12 at 1:39 AM
Karyopharm Therapeutics Stock Sees Short Interest Increase 16.4%Karyopharm Therapeutics Stock Sees Short Interest Increase 16.4%
www.thestreet.com - November 12 at 1:39 AM
Karyopharm Therapeutics Inc. (KPTI) SVP Sells $55,777.50 in StockKaryopharm Therapeutics Inc. (KPTI) SVP Sells $55,777.50 in Stock
www.americanbankingnews.com - November 9 at 7:50 PM
Karyopharm Therapeutics, Inc. – Value Analysis (NASDAQ:KPTI) : November 7, 2017Karyopharm Therapeutics, Inc. – Value Analysis (NASDAQ:KPTI) : November 7, 2017
finance.yahoo.com - November 8 at 12:49 PM
FY2017 EPS Estimates for Karyopharm Therapeutics Inc. Lifted by Analyst (KPTI)FY2017 EPS Estimates for Karyopharm Therapeutics Inc. Lifted by Analyst (KPTI)
www.americanbankingnews.com - November 8 at 11:24 AM
Karyopharm Therapeutics Inc. (KPTI) Given Average Rating of "Buy" by AnalystsKaryopharm Therapeutics Inc. (KPTI) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 6 at 1:33 PM
Karyopharm Therapeutics (KPTI) CEO Michael Kauffman on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaKaryopharm Therapeutics' (KPTI) CEO Michael Kauffman on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 6 at 5:55 AM
FY2017 EPS Estimates for Karyopharm Therapeutics Inc. (KPTI) Lowered by AnalystFY2017 EPS Estimates for Karyopharm Therapeutics Inc. (KPTI) Lowered by Analyst
www.americanbankingnews.com - November 6 at 4:36 AM
Royal Bank Of Canada Reaffirms Buy Rating for Karyopharm Therapeutics Inc. (KPTI)Royal Bank Of Canada Reaffirms Buy Rating for Karyopharm Therapeutics Inc. (KPTI)
www.americanbankingnews.com - November 4 at 4:10 PM
Karyopharm Therapeutics Inc. (KPTI) Earns "Buy" Rating from Robert W. BairdKaryopharm Therapeutics Inc. (KPTI) Earns "Buy" Rating from Robert W. Baird
www.americanbankingnews.com - November 4 at 12:36 AM
Karyopharm Therapeutics to Participate in the Credit Suisse 26th Annual Healthcare Conference - GlobeNewswire (press release)Karyopharm Therapeutics to Participate in the Credit Suisse 26th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 3 at 6:14 PM
Karyopharm Therapeutics, Inc. to Host Earnings CallKaryopharm Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 3 at 1:12 PM
Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent ProgressKaryopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress
finance.yahoo.com - November 3 at 1:12 PM
Karyopharm Therapeutics posts 3Q lossKaryopharm Therapeutics posts 3Q loss
finance.yahoo.com - November 3 at 1:12 PM
Edited Transcript of KPTI earnings conference call or presentation 2-Nov-17 12:30pm GMTEdited Transcript of KPTI earnings conference call or presentation 2-Nov-17 12:30pm GMT
finance.yahoo.com - November 3 at 1:12 PM
Karyopharm Therapeutics Inc. (KPTI) Announces  Earnings ResultsKaryopharm Therapeutics Inc. (KPTI) Announces Earnings Results
www.americanbankingnews.com - November 2 at 5:35 PM
Karyopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual MeetingKaryopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual Meeting
finance.yahoo.com - November 2 at 4:40 AM
Karyopharm Therapeutics Inc. (KPTI) Set to Announce Earnings on ThursdayKaryopharm Therapeutics Inc. (KPTI) Set to Announce Earnings on Thursday
www.americanbankingnews.com - October 28 at 10:38 AM
Karyopharm to Report Third Quarter 2017 Financial Results on November 2, 2017Karyopharm to Report Third Quarter 2017 Financial Results on November 2, 2017
finance.yahoo.com - October 26 at 4:45 PM
Royal Bank Of Canada Reaffirms "Buy" Rating for Karyopharm Therapeutics Inc. (KPTI)Royal Bank Of Canada Reaffirms "Buy" Rating for Karyopharm Therapeutics Inc. (KPTI)
www.americanbankingnews.com - October 18 at 12:04 PM
Karyopharm Therapeutics (KPTI) PT Raised to $18 at Wedbush - StreetInsider.comKaryopharm Therapeutics (KPTI) PT Raised to $18 at Wedbush - StreetInsider.com
www.streetinsider.com - October 15 at 12:48 AM
Karyopharm Jumps on Deal with ONOKaryopharm Jumps on Deal with ONO
www.baystreet.ca - October 14 at 7:46 PM
Jefferies Group LLC Reaffirms Buy Rating for Karyopharm Therapeutics Inc. (KPTI)Jefferies Group LLC Reaffirms Buy Rating for Karyopharm Therapeutics Inc. (KPTI)
www.americanbankingnews.com - October 14 at 7:40 AM
Karyopharm Therapeutics (KPTI) Reports Exclusive License Agreement with Ono Pharmaceutical Co. to Develop ... - StreetInsider.comKaryopharm Therapeutics (KPTI) Reports Exclusive License Agreement with Ono Pharmaceutical Co. to Develop ... - StreetInsider.com
www.streetinsider.com - October 13 at 6:17 AM
Cantor Fitzgerald Analysts Give Karyopharm Therapeutics Inc. (KPTI) a $18.00 Price TargetCantor Fitzgerald Analysts Give Karyopharm Therapeutics Inc. (KPTI) a $18.00 Price Target
www.americanbankingnews.com - October 13 at 12:32 AM

SEC Filings

Karyopharm Therapeutics (NASDAQ:KPTI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Karyopharm Therapeutics (NASDAQ:KPTI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Karyopharm Therapeutics (NASDAQ KPTI) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.